Eupraxia Pharmaceuticals (EPRX) Research & Development (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Research & Development data on file, last reported at $11.2 million in Q1 2026.

• On a quarterly basis, Research & Development rose 190.25% year-over-year to $11.2 million in Q1 2026; TTM through Mar 2026 was $28.7 million, a 78.57% increase from a year earlier, with the FY2025 full-year figure at $21.3 million, up 32.67% from the prior year.
• Research & Development for Q1 2026 stood at $11.2 million, up from $7.9 million in the prior quarter.
• Over the last five years, Research & Development for EPRX reached as high as $11.2 million in Q1 2026 and fell as low as $2.3 million in Q1 2023.
• Historically, Research & Development has averaged $5.6 million across 4 years, with a median of $4.4 million in 2025.
• Across the five-year window, Research & Development sank 58.38% in 2024 and soared 190.25% in 2026, its largest moves.
• Year by year, Research & Development stood at $9.5 million in 2023, then sank by 58.38% to $4.0 million in 2024, then jumped by 98.08% to $7.9 million in 2025, then surged by 42.03% to $11.2 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $11.2 million in Q1 2026, $7.9 million in Q4 2025, and $4.4 million in Q3 2025.